Adebrelimab
Gastrointestinal Tumours
China Medical University, ChinaActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Gastrointestinal Tumours cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Regorafenib China Medical University, China | D | |
Fruquintinib China Medical University, China | D |
Same molecule, other indications
Adebrelimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →